A carregar...
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
Abiraterone treats metastatic castrate-resistant prostate cancer by inhibiting CYP17A, an enzyme for testosterone auto-production. With standard dosing, evolution of resistance with treatment failure (radiographic progression) occurs at a median of ~16.5 months. We hypothesize time to progression (T...
Na minha lista:
| Publicado no: | Nat Commun |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5703947/ https://ncbi.nlm.nih.gov/pubmed/29180633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-01968-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|